Hasil Pencarian  ::  Simpan CSV :: Kembali

"Pendahuluan: Hiperurisemia sering terjadi pada pasien DM tipe 2, hal ini disebabkan adanya penurunan ekskresi asam urat yang berkaitan dengan resistensi insulin (RI) dan hiperinsulinemia. Tujuan dari penelitian ini adalah untuk mengetahui efek α-mangostin terhadap fungsi ginjal dan kadar asam urat dalam plasma darah tikus model resistensi insulin. Metode: Tikus jantan galur wistar dibagi menjadi 6 kelompok secara acak: normal, normal yang diberi α-mangostin 200 mg/kgBB, RI, RI yang diberi metformin 200 mg/kgBB, RI yang diberi α-mangostin 100 mg/kgBB dan RI yang diberi α- mangostin 200 mg/kgBB. Pemberian α-mangostin dan metformin dilakukan selama 8 minggu dan diberikan secara peroral. Kelompok perlakuan diberi diet tinggi lemak, glukosa 20% dan induksi STZ dosis rendah. Pada akhir penelitian, sampel urin, darah dan ginjal diambil dan diukur proteinuria, BUN, klirens kreatinin, asam urat plasma, transporter URAT1, GLUT9, SGLT2 dan histopatologi ginjal. Hasil: α-mangostin 100 mg/kgBB dan 200 mg/kgBB mampu menurunkan BUN dan asam urat plasma secara signifikan, α-mangostin 100 mg/kgBB dan 200 mg/kgBB cenderung menurunkan proteinuria, meningkatkan klirens kreatinin, menurunkan ekspresi URAT1, GLUT9, SGLT2 serta memperbaiki kerusakan ginjal dibandingkan dengan kelompok RI tanpa pengobatan. Kesimpulan: α-mangostin 100 mg/kgBB dan 200 mg/kgBB mampu menurunkan kadar asam urat plasma dan cenderung memperbaiki fungsi ginjal pada tikus model RI.......Background: Hyperuricemia often occurs in type 2 diabetes mellitus, this is due to a decrease in uric acid excretion associated with insulin resistance (IR) and hyperinsulinemia. The aim of this study was to analyze the effects of α-mangostin on kidney function and plasma uric acid level of insulin resistance rat model. Method: Wistar male rats were divided into 6 groups, such as normal, normal + α- mangostin 200 mg/kgBW, IR, IR + metformin 200 mg/kgBW, IR + α-mangostin 100 mg/kgBW and IR + 200 mg/kgBW. -mangostin and metformin were administered by gavage for 8 weeks. To induce IR, treatment groups were given a high-fat diet, glucose 20%, and low-dose injection of STZ. At the end of the study, urine, blood, and kidney tissue were taken and measured proteinuria, BUN, creatinine clearance, plasma uric acid, expressions of URAT1, GLUT9, and SGLT2 as well as kidney histopathology Results: -mangostin 100 mg/kgBW and 200 mg/kgBW were able to significantly reduce BUN and plasma uric acid levels. -mangostin 100 mg/kgBW and 200 mg/kgBW tended to reduce proteinuria, increase creatinine clearance, reduce the expression of URAT1, GLUT9, SGLT2, as well as improve renal damage compared to that of IR untreated group. Conclusion: -mangostin 100 mg/kgBW and 200 mg/kgBW were able to reduce plasma uric acid levels dan tended to alleviate renal dysfunction in IR rat model."

"Latar belakang. Hiperurisemia merupakan salah satu parameter metabolik yang diperkirakan mempunyai peranan dalam perjalanan non-alcoholic liver disease NAFLD . Studi mengenai peranan asam urat dalam progresivitas penyakit hati masih terbatas. Tujuan. Mengetahui korelasi antara kadar asam urat dengan nilai Elastografi Transien ET dan Controlled Attenuation Parameter CAP pasien NAFLD. Metode. Penelitian ini merupakan studi potong lintang dengan menggunakan data sekunder yang melibatkan 113 pasien NAFLD dewasa. Dilakukan uji korelasi antara kadar asam urat dengan nilai ET dan nilai CAP. Lalu dilakukan analisis tambahan dengan membagi pasien menjadi 2 kelompok berdasarkan nilai ET dan CAP. Nilai titik potong ET untuk fibrosis signifikan sebesar ge; 7 kPa dan nilai CAP ge; 285 dB/m digunakan untuk membedakan steatosis ringan dan steatosis sedangberat. Faktor metabolik yang mempengaruhi derajat steatosis dan fibrosis dianalisis dengan menggunakan uji chi-square dan dilakukan analisis regresi logistik. Hasil. Terdapat 45 pasien dengan steatosis sedang-berat dan 34 pasien yang mengalami fibrosis signifikan. Tidak terdapat korelasi antara kadar asam urat dengan nilai CAP koefisien korelasi r = 0,2 dan p=0,026 maupun nilai ET r = 0,151 dan p = 0,110 . Terdapat perbedaan rerata kadar asam urat antara kelompok steatosis ringan dibandingkan steatosis sedang-berat 6,31 1,44 mg/dL vs 6,94 1,62 mg/dL, p = 0,03 . Tidak terdapat hubungan independen antara hiperurisemia dan derajat steatosis. Sedangkan faktor yang berhubungan secara independen dengan derajat fibrosis signifikan adalah hiperurisemia OR 2,450; 95 IK 1,054- 5,697 dan kenaikan kadar glukosa puasa OR 3,988 1,105-14,389 . Kelompok fibrosis signifikan mempunyai nilai rerata kadar asam urat yang lebih tinggi 6,89 1,60 mg/dL vs 6,42 1,50 mg/dL walau tidak bermakna secara statistik nilai p = 0,145. Kesimpulan. Tidak terdapat korelasi antara kadar asam urat dengan nilai ET dan CAP. ......Background. Hyperuricemia is one of metabolic parameter which has been considered to play an important role in NAFLD. There is still lack of studies or evidence about correlation between serum uric acid level with liver disease progression. Aim of the study. To know the correlation between serum uric acid level and the steatosis and fibrosis degree of non alcoholic fatty liver disease evaluated using Controlled Attenuation Parameter CAP Transient Elastography TE examination. Methods. This study is a cross sectional study using secondary data of 113 NAFLD. Correlation between uric acid level and the degree of steatosis and fibrosis were also evaluated. Cutoff value for significant liver fibrosis ge 7 kPa. Mild and moderate severe steatosis diagnosed with a cutoff value of ge 285 dB m. Each metabolic factors were analyzed using chi square test. Univariate and multivariate analysis were performed using logistic regression test. Results. Of 113 NAFLD patients, there were 45 patients with moderate severe steatosis and 34 patients with significant fibrosis. There was no correlation between uric acid level and CAP correlation coefficient 0.2, P 0.026 and ET correlation coefficient 0.151, P 1,110 value were found. The difference of uric acid level mean value was found between mild steatosis and moderate severe steatosis 6.31 1.44 mg dL vs. 6.94 162 mg dL, P 0,03 . Hyperuricemia was not independent risk factor of moderate severe steatosis. High level of fasting blood glucose OR 3.98, 95 CI 1.105 14.389 and hyperuricemia OR 2.501, 95 CI 1.095 5.714 were found to be independent risk factors for significant liver fibrosis. Significant liver fibrosis group tends to have a higher mean value of uric acid level 6.89 1.60 mg dL vs. 6.42 1,50 mg dL with a p value 0,145. Conclusion. There was no correlation between uric acid an CAP TE value."